Castleark Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-181,595
| Closed | -$13.5M | – | 297 |
|
|
2022
Q4 | $13.5M | Sell |
181,595
-239,900
| -57% | -$18.5M | 0.71% | 34 |
|
|
2022
Q3 | $34.8M | Buy |
421,495
+8,530
| +2% | +$821K | 1.94% | 12 |
|
|
2022
Q2 | $39.3M | Buy |
412,965
+46,150
| +13% | +$4.78M | 2.1% | 14 |
|
|
2022
Q1 | $43.2M | Sell |
366,815
-19,680
| -5% | -$2.21M | 1.86% | 15 |
|
|
2021
Q4 | $50.1M | Sell |
386,495
-840
| -0.2% | -$98K | 1.84% | 14 |
|
|
2021
Q3 | $43.9M | Sell |
387,335
-51,950
| -12% | -$5.93M | 1.68% | 13 |
|
|
2021
Q2 | $45.5M | Buy |
439,285
+205,240
| +88% | +$19.3M | 1.53% | 16 |
|
|
2021
Q1 | $19.6M | Buy |
234,045
+12,150
| +5% | +$1.03M | 0.7% | 36 |
|
|
2020
Q4 | $20.2M | Sell |
221,895
-6,035
| -3% | -$501K | 0.76% | 35 |
|
|
2020
Q3 | $18.2M | Buy |
227,930
+27,520
| +14% | +$2.15M | 0.71% | 36 |
|
|
2020
Q2 | $13.8M | Buy |
200,410
+190,900
| +2,007% | +$13.6M | 0.6% | 38 |
|
|
2020
Q1 | $598K | Buy |
9,510
+5,190
| +120% | +$374K | 0.04% | 218 |
|
|
2019
Q4 | $336K | Sell |
4,320
-3,240
| -43% | -$253K | 0.01% | 299 |
|
|
2019
Q3 | $554K | Hold |
7,560
| – | – | 0.02% | 274 |
|
|
2019
Q2 | $466K | Sell |
7,560
-4,410
| -37% | -$267K | 0.02% | 295 |
|
|
2019
Q1 | $763K | Hold |
11,970
| – | – | 0.03% | 275 |
|
|
2018
Q4 | $611K | Sell |
11,970
-228,780
| -95% | -$11.6M | 0.03% | 284 |
|
|
2018
Q3 | $14M | Sell |
240,750
-291,441
| -55% | -$14.3M | 0.4% | 84 |
|
|
2018
Q2 | $25.8M | Buy |
532,191
+522,621
| +5,461% | +$24.4M | 0.79% | 27 |
|
|
2018
Q1 | $445K | Buy |
9,570
+2,190
| +30% | +$95.1K | 0.01% | 318 |
|
|
2017
Q4 | $277K | Buy |
7,380
+2,670
| +57% | +$98K | 0.01% | 347 |
|
|
2017
Q3 | $172K | Sell |
4,710
-288,090
| -98% | -$11M | 0.01% | 362 |
|
|
2017
Q2 | $11.5M | Sell |
292,800
-234,312
| -44% | -$8.55M | 0.38% | 85 |
|
|
2017
Q1 | $16.5M | Sell |
527,112
-449,037
| -46% | -$14.1M | 0.52% | 45 |
|
|
2016
Q4 | $30.5M | Sell |
976,149
-611,841
| -39% | -$19.8M | 0.97% | 22 |
|
|
2016
Q3 | $63.8M | Sell |
1,587,990
-83,910
| -5% | -$3.16M | 1.93% | 1 |
|
|
2016
Q2 | $55.6M | Sell |
1,671,900
-158,640
| -9% | -$5.43M | 1.77% | 6 |
|
|
2016
Q1 | $53.8M | Buy |
1,830,540
+130,290
| +8% | +$3.6M | 1.68% | 9 |
|
|
2015
Q4 | $44.8M | Sell |
1,700,250
-28,350
| -2% | -$736K | 1.35% | 20 |
|
|
2015
Q3 | $41M | Sell |
1,728,600
-73,200
| -4% | -$1.77M | 1.32% | 21 |
|
|
2015
Q2 | $42.8M | Buy |
1,801,800
+961,320
| +114% | +$21.7M | 1.14% | 20 |
|
|
2015
Q1 | $20M | Buy |
+840,480
| New | +$18.9M | 0.48% | 50 |
|
Other funds holding EW
Castleark Management's EW Position: Q1 2023 in Review
Castleark Management sold out of Edwards Lifesciences (EW) in Q1 2023, closing a stake of 181,595 shares — an estimated $13.5M sold.
Castleark Management first reported a position in EW in Q1 2015 and held it in 32 quarters. The position peaked at $63.8M in Q3 2016. 1,246 funds tracked by Wall St. Rank hold EW as of Q1 2023.
- Castleark Management reported no remaining Edwards Lifesciences position as of Q1 2023 after selling out during the quarter.
- Castleark Management sold 181,595 Edwards Lifesciences shares in Q1 2023, an estimated $13.5M.
- Castleark Management first reported a position in Edwards Lifesciences in Q1 2015 and held it in 32 quarters.
- Castleark Management's Edwards Lifesciences position peaked at $63.8M in Q3 2016.
- 1,246 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2023.
Based on Castleark Management's 13F filing for Q1 2023, filed 16 May 2023.